Industry
Biotechnology
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Loading...
Open
1.95
Mkt cap
579M
Volume
903K
High
2.03
P/E Ratio
-3.33
52-wk high
4.44
Low
1.89
Div yield
N/A
52-wk low
1.12
Portfolio Pulse from Benzinga Newsdesk
October 14, 2024 | 11:33 am
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 1:30 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 11:55 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 9:47 am
Portfolio Pulse from Benzinga Newsdesk
September 04, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 11:39 am
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 11:17 am
Portfolio Pulse from Avi Kapoor
June 26, 2024 | 12:37 pm
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 6:25 am
Portfolio Pulse from Avi Kapoor
June 11, 2024 | 5:54 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.